Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.13 -4.2%	$1.20	$0.86 ▼ $3.78	$261.82M	0.35	5.62 million shs	3.34 million shs
CMMB Chemomab Therapeutics	$3.14 -7.9%	$4.20	$3.10 ▼ $10.20	$16.08M	0.52	94,096 shs	283,391 shs
JBIO Jade Biosciences	$7.90 -2.2%	$8.62	$6.57 ▼ $105.00	$263.62M	1.03	109,823 shs	47,960 shs
LXEO Lexeo Therapeutics	$4.79 +0.6%	$4.45	$1.45 ▼ $11.96	$257.05M	1.36	305,068 shs	232,724 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	+1.72%	+5.36%	-15.71%	+1.29%	-54.09%
CMMB Chemomab Therapeutics	-2.01%	-3.67%	-21.79%	-34.42%	-54.17%
JBIO Jade Biosciences	+1.64%	+9.49%	+7.30%	+807,999,900.00%	+807,999,900.00%
LXEO Lexeo Therapeutics	-1.86%	-0.42%	+16.10%	+72.46%	-58.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	2.8143 of 5 stars	3.4	3.0	2.6	2.5	0.6
CMMB Chemomab Therapeutics	3.1897 of 5 stars	3.5	5.0	2.5	1.7	0.6
JBIO Jade Biosciences	2.1037 of 5 stars	3.5	0.0	3.1	1.7	0.0
LXEO Lexeo Therapeutics	2.6265 of 5 stars	3.5	1.0	3.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.75	Moderate Buy	$8.44	647.30% Upside
CMMB Chemomab Therapeutics	3.00	Buy	$26.50	743.95% Upside
JBIO Jade Biosciences	3.00	Buy	$16.00	102.53% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$15.33	220.11% Upside

Current Analyst Ratings Breakdown

Latest CMMB, JBIO, LXEO, and ALLO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	CMMB Chemomab Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$10.00 ➝ $25.00
8/15/2025	LXEO Lexeo Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $15.00
8/15/2025	LXEO Lexeo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $9.00
8/14/2025	JBIO Jade Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$17.00 ➝ $18.00
8/4/2025	ALLO Allogene Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
8/4/2025	ALLO Allogene Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
7/31/2025	LXEO Lexeo Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$20.00
7/14/2025	JBIO Jade Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$16.00
6/16/2025	JBIO Jade Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$14.00
5/30/2025	LXEO Lexeo Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$16.00 ➝ $10.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	12,536.22	N/A	N/A	$1.55 per share	0.73
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	$2.06 per share	N/A
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	$6.18 per share	N/A
LXEO Lexeo Therapeutics	$650K	397.94	N/A	N/A	$2.56 per share	1.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$257.59M	-$1.11	N/A	N/A	N/A	N/A	-55.99%	-42.75%	11/6/2025 (Estimated)
CMMB Chemomab Therapeutics	-$13.94M	-$0.59	N/A	N/A	N/A	N/A	-94.71%	-76.53%	11/13/2025 (Estimated)
JBIO Jade Biosciences	-$69.63M	-$30.33	N/A	∞	N/A	N/A	-51.96%	-47.65%	N/A
LXEO Lexeo Therapeutics	-$98.33M	-$3.26	N/A	N/A	N/A	N/A	-94.65%	-73.36%	11/12/2025 (Estimated)

Latest CMMB, JBIO, LXEO, and ALLO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CMMB Chemomab Therapeutics	-$0.80	-$0.36	+$0.44	-$0.09	N/A	N/A
8/14/2025	Q2 2025	LXEO Lexeo Therapeutics	-$0.64	-$0.60	+$0.04	-$0.60	N/A	N/A
8/13/2025	Q2 2025	ALLO Allogene Therapeutics	-$0.28	-$0.23	+$0.05	-$0.23	N/A	N/A
8/13/2025	Q2 2025	JBIO Jade Biosciences	-$0.43	-$0.86	-$0.43	-$0.86	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
CMMB Chemomab Therapeutics	N/A	N/A	N/A	N/A	N/A
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	8.92	8.92
CMMB Chemomab Therapeutics	N/A	7.42	7.42
JBIO Jade Biosciences	N/A	10.31	10.31
LXEO Lexeo Therapeutics	N/A	4.43	4.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
CMMB Chemomab Therapeutics	46.05%
JBIO Jade Biosciences	N/A
LXEO Lexeo Therapeutics	60.67%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
CMMB Chemomab Therapeutics	11.91%
JBIO Jade Biosciences	24.90%
LXEO Lexeo Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	221.88 million	192.59 million	Optionable
CMMB Chemomab Therapeutics	20	4.71 million	4.15 million	Not Optionable
JBIO Jade Biosciences	20	32.63 million	24.50 million	N/A
LXEO Lexeo Therapeutics	58	54.00 million	51.14 million	Not Optionable

CMMB, JBIO, LXEO, and ALLO Headlines

Recent News About These Companies

Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth?

August 29 at 6:42 AM | finance.yahoo.com

Affinity Asset Advisors LLC Acquires Shares of 1,480,881 Lexeo Therapeutics, Inc. $LXEO

August 28 at 9:02 AM | marketbeat.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $15.33 Average Target Price from Analysts

August 28 at 2:09 AM | americanbankingnews.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Buy" from Analysts

August 27 at 3:21 AM | marketbeat.com

What is Chardan Capital's Forecast for LXEO FY2025 Earnings?

August 23, 2025 | marketbeat.com

Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 2,735 Shares of Stock

August 21, 2025 | insidertrades.com

Lexeo Therapeutics’ Friedreich Ataxia Gene Therapy Receives FDA Breakthrough Therapy Designation

August 20, 2025 | msn.com

Lexeo Therapeutics (NASDAQ:LXEO) Given New $15.00 Price Target at Chardan Capital

August 17, 2025 | marketbeat.com

Lexeo Therapeutics (NASDAQ:LXEO) Announces Earnings Results

August 17, 2025 | marketbeat.com

Lexeo Therapeutics (NASDAQ:LXEO) Given New $9.00 Price Target at HC Wainwright

August 17, 2025 | marketbeat.com

Lexeo Therapeutics price target lowered to $15 from $20 at Chardan

August 16, 2025 | msn.com

Lexeo Therapeutics reports Q2 EPS (60c) vs (64c) last year

August 14, 2025 | msn.com

Lexeo Therapeutics Appoints New Chief Financial Officer

August 14, 2025 | tipranks.com

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

August 14, 2025 | globenewswire.com

Lexeo Therapeutics (NASDAQ:LXEO) Shares Up 1.8% - What's Next?

August 10, 2025 | marketbeat.com

Lexeo Therapeutics (LXEO) Projected to Post Quarterly Earnings on Monday

August 5, 2025 | marketbeat.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Buy" from Brokerages

August 1, 2025 | marketbeat.com

Lexeo Therapeutics (NASDAQ:LXEO) Coverage Initiated by Analysts at Oppenheimer

August 1, 2025 | marketbeat.com

Oppenheimer Initiates Coverage of Lexeo Therapeutics (LXEO) with Outperform Recommendation

August 1, 2025 | msn.com

Stifel Maintains Buy Rating on Lexeo Therapeutics (LXEO)

July 29, 2025 | msn.com

Lexeo Therapeutics Holds 2025 Annual Stockholders Meeting

July 25, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB, JBIO, LXEO, and ALLO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.13 -0.05 (-4.24%)

Closing price 04:00 PM Eastern

Extended Trading

$1.14 +0.01 (+1.24%)

As of 07:18 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Chemomab Therapeutics NASDAQ:CMMB

$3.14 -0.27 (-7.92%)

Closing price 04:00 PM Eastern

Extended Trading

$3.20 +0.06 (+2.07%)

As of 07:57 PM Eastern

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Jade Biosciences NASDAQ:JBIO

$7.90 -0.18 (-2.23%)

As of 04:00 PM Eastern

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Lexeo Therapeutics NASDAQ:LXEO

$4.79 +0.03 (+0.63%)

Closing price 04:00 PM Eastern

Extended Trading

$4.80 +0.01 (+0.21%)

As of 06:48 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time